RIGEL: 30 job cuts, new fostamatinib-led strategy

It's been a difficult year for Rigel Pharmaceuticals and it just got tougher for 30 of the company's employees, since Rigel decided to restructure its operations after fostamatinib failed earlier this year in three Phase III rheumatoid arthritis clinical trials.

It's been a difficult year for Rigel Pharmaceuticals and it just got tougher for 30 of the company's employees, since Rigel decided to restructure its operations after fostamatinib failed earlier this year in three Phase III rheumatoid arthritis clinical trials.

The South San Francisco-based company's stock is trading for less than half of its 2013 peak of $7.53 per share,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category